The trial evaluates Numinus’ first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 /CNW/ – Numinus Wellness Inc. (“Numinus”) (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application (“CTA”) to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe…


Previous articlePT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care
Next articlePsychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021